Skip to main content

Advertisement

SpringerLink
Log in

Transfusion as a Palliative Strategy

  • Palliative Medicine (A Jatoi, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The palliative care population is a complex and heterogeneous one. While transfusion therapy is a readily available intervention for many patients, inadequate knowledge for accurately identifying which patient subsets at end-of-life will benefit from a transfusion, along with an unclear understanding of the magnitude of attendant risks of transfusion in those receiving palliative care, complicates the risk-benefit assessment of this therapy. In this brief review, the current literature surrounding transfusion of red cells and platelets in the palliative care patient population will be reviewed and recommendations provided.

Recent Findings

Benefits of transfusion therapy include subjective relief of fatigue and dyspnea, and improved sense of wellness, amongst other findings. However, these responses are not durable and there are currently no validated, objective metrics that correlate with symptomatic improvements. It is clear that transfusion-associated adverse reactions are underestimated in those receiving palliative care, with reaction rates similar to the general patient population. Additionally, based on the high mortality rates reported soon after transfusion, the impact of these blood components must be considered as an exacerbating or causative factor of mortality when evaluating declining condition or death. Hematinics are rarely assessed in anemic palliative care patients or, when measured, are often not corrected. The decision to transfuse palliative care patients is multifactorial, and benefits, risks, patient wishes, blood component inventories, and alternatives to transfusion should all be considered.

Summary

There are many unknowns regarding transfusion in palliative care. Critical next steps for optimizing blood component therapy in this population include high-quality trials that help to identify validated measures of objective functional changes that parallel patient-reported outcomes and subsets of patients receiving end-of-life care that will most likely be positively impacted by transfusion therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. World Health Organization (WHO). WHO definition of palliative care. Geneva: WHO; 2017. http://www.who.int/cancer/palliative/definition/en/. Accessed 1 Jan 2019.

  2. Raval JS, Cooling LL. Red blood cell transfusion in palliative care: what are we doing and why are we doing it? Transfusion. 2018;58:3–4.

    Article  Google Scholar 

  3. Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Chung KW, et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;57(Suppl 2):1588–98.

    Article  Google Scholar 

  4. • Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162:205–13 These evidence-based platelet guidelines are based on a systematic review of randomized clinical trials and observational studies.

    Article  Google Scholar 

  5. • Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316:2025–35 These evidence-based red cell transfusion guidelines are based on a systematic review of randomized clinical trials.

    Article  Google Scholar 

  6. Douglas SP, Crook ED, Reynolds MD, Robinson CG, Kirchner KA. There is power in the blood: a case discussing ethical issues of utility of resources. Am J Med Sci. 2001;322:145–50.

    Article  CAS  Google Scholar 

  7. Rubin M. Should we offer blood transfusions as a palliative therapy? Am J Bioeth. 2016;16:62–4.

    Article  Google Scholar 

  8. Sherbeck JP, Boss RD. Ethical questions about platelet transfusions at the end of life. AMA J Ethics. 2016;18:764–70.

    Article  Google Scholar 

  9. Smith LB, Cooling L, Davenport R. How do I allocate blood products at the end of life? An ethical analysis with suggested guidelines. Transfusion. 2013;53:696–700.

    Article  Google Scholar 

  10. Beauchamp TL, Childress JF. Principles of biomedical ethics. ed 5th ed. New York: Oxford University Press; 2001.

    Google Scholar 

  11. Preston NJ, Hurlow A, Brine J, Bennett MI. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev. (2012):CD009007.

  12. Uceda Torres ME, Rodriguez Rodriguez JN, Sanchez Ramos JL, Alvarado Gomez F. Transfusion in palliative cancer patients: a review of the literature. J Palliat Med. 2014;17:88–104.

    Article  Google Scholar 

  13. • Chin-Yee N, Taylor J, Rourke K, Faig D, Davis A, Fergusson D, et al. Red blood cell transfusion in adult palliative care: a systematic review. Transfusion. 2018;58:233–41 A recent systematic review specifically focusing on red blood cell transfusion in palliative care patients.

    Article  Google Scholar 

  14. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;(10):CD002042.

  15. Tobian AA, Heddle NM, Wiegmann TL, Carson JL. Red blood cell transfusion: 2016 clinical practice guidelines from AABB. Transfusion. 2016;56:2627–30.

    Article  Google Scholar 

  16. Gleeson C, Spencer D. Blood transfusion and its benefits in palliative care. Palliat Med. 1995;9:307–13.

    Article  CAS  Google Scholar 

  17. Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med. 2009;12:60–3.

    Article  Google Scholar 

  18. To TH, To LB, Currow DC. Can we detect transfusion benefits in palliative care patients? J Palliat Med. 2016;19:1110–3.

    Article  Google Scholar 

  19. To THM, LeBlanc TW, Eastman P, Neoh K, Agar MR, To LB, et al. The prospective evaluation of the net effect of red blood cell transfusions in routine provision of palliative care. J Palliat Med. 2017;20:1152–7.

    Article  Google Scholar 

  20. •• Neoh K, Gray R, Grant-Casey J, Estcourt L, Malia C, Boland JW, et al. National comparative audit of red blood cell transfusion practice in hospices: Recommendations for palliative care practice. Palliat Med. 2019;33:102–8 A prospective study showing that palliative care patients are not routinely investigated for causes of anemia, corrective supplementations are rarely provided when such investigations are performed, and the practice of red cell transfusion is too liberal.

    Article  Google Scholar 

  21. Cartoni C, Niscola P, Breccia M, Brunetti G, D'Elia GM, Giovannini M, et al. Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma. 2009;50:387–91.

    Article  Google Scholar 

  22. Brook L, Vickers J, Pizer B. Home platelet transfusion in pediatric oncology terminal care. Med Pediatr Oncol. 2003;40:249–51.

    Article  Google Scholar 

  23. Lassauniere JM, Bertolino M, Hunault M, Zittoun R, Verspieren P, Moh-Klaren J, et al. Platelet transfusions in advanced hematological malignancies: a position paper. J Palliat Care. 1996;12:38–41.

    Article  CAS  Google Scholar 

  24. Mannis GN, McNey LM, Gupta NK, Gross DM. The transfusion tether: bridging the gap between end-stage hematologic malignancies and optimal end-of-life care. Am J Hematol. 2016;91:364–5.

    Article  Google Scholar 

  25. • Delaney M, Wendel S, Bercovitz RS, Cid J, Cohn C, Dunbar NM, et al. Biomedical excellence for safer transfusion C: transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388:2825–36 A succinct yet thorough review of transfusion reaction investigation, management, and prevention.

    Article  Google Scholar 

  26. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52:160–5.

    Article  Google Scholar 

  27. Raval JS, Mazepa MA, Russell SL, Immel CC, Whinna HC, Park YA. Passive reporting greatly underestimates the rate of transfusion-associated circulatory overload after platelet transfusion. Vox Sang. 2015;108:387–92.

    Article  CAS  Google Scholar 

  28. Martinsson U, Lundstrom S. The use of blood transfusions and erythropoietin-stimulating agents in Swedish palliative care. Support Care Cancer. 2009;17:199–203.

    Article  Google Scholar 

  29. Stone P, Kurowska A, Tookman A. Blood transfusion in palliative care. Palliat Med. 1996;10:166.

    Article  CAS  Google Scholar 

  30. Sirianni G, Perri G, Callum J, Gardner S, Berall A, Selby D. A retrospective chart review of transfusion practices in the palliative care unit setting. Am J Hosp Palliat Care. 2018:1049909118806456. https://doi.org/10.1177/1049909118806456.

    Article  Google Scholar 

  31. U.S. Food and Drug Administration (FDA). Fatalities reported to FDA following blood collection and transfusion annual summary for fiscal year 2016. Silver Spring: FDA; 2016. https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM598243.pdf. Accessed 1 Jan 2019.

  32. Cheng BH, Sham MM, Chan KY, Li CW, Au HY. Intensive palliative care for patients with hematological cancer dying in hospice: analysis of the level of medical care in the final week of life. Am J Hosp Palliat Care. 2015;32:221–5.

    Article  Google Scholar 

  33. Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney C, et al. Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018;26:1927–31.

    Article  Google Scholar 

  34. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50:753–65.

    Article  Google Scholar 

  35. Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018;21:827–34.

    Article  Google Scholar 

  36. British Committee for Standards in Hematology. Guideline on the administration of blood components, 2012 addendum to 2009 guidelines on administration of blood components. 2012. http://www.b-s-h.org.uk/media/13489/bcsh-blood-admin-addendum-august-2012.pdf. Accessed 1 Jan 2019.

  37. • National Institute for Health and Care Excellence (NICE). NICE guideline [NG24]: Blood transfusion. London: NICE; 2015. https://www.nice.org.uk/guidance/ng24. Accessed 1 Jan 2019. U.K. transfusion guidelines for adults recommending a restrictive transfusion strategy and alternatives to transfusion.

  38. de Putter R, Geboes K, De Man M, Van Belle S. Treatment of anemia in patients with solid tumors receiving chemotherapy in palliative setting: usual practice versus guidelines. Acta Clin Belg. 2018;73:251–6.

    Article  Google Scholar 

  39. •• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for cancer- and chemotherapy-induced anemia, Version 2.2018. Plymouth Meeting: NCCN 2018. https://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf. Accessed 1 Jan 2019. Comprehensive guidelines for transfusion therapy in cancer patients recommending a restrictive transfusion strategy along with correction of underlying causes of anemia.

  40. • Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascon P, Glaspy J, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29:iv271 European transfusion guidelines for oncology patients recommending a restrictive transfusion strategy.

    Article  CAS  Google Scholar 

  41. Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in H. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166:496–513.

    Article  CAS  Google Scholar 

  42. Valeri CR, Cassidy G, Pivacek LE, Ragno G, Lieberthal W, Crowley JP, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion. 2001;41:977–83.

    Article  CAS  Google Scholar 

  43. Valeri CR, Khuri S, Ragno G. Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma-clotting proteins. Transfusion. 2007;47:206S–48S.

    Article  CAS  Google Scholar 

  44. Silvain J, Abtan J, Kerneis M, Martin R, Finzi J, Vignalou JB, et al. Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry). J Am Coll Cardiol. 2014;63:1289–96.

    Article  Google Scholar 

  45. • Desborough M, Hadjinicolaou AV, Chaimani A, Trivella M, Vyas P, Doree C, et al. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. Cochrane Database Syst Rev. 2016;10:CD012055 A systematic review evaluating alternatives to platelet transfusion therapy in those with thrombocytopenia and marrow failure.

    PubMed  Google Scholar 

  46. ClinicalTrials.gov: TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia (TREATT). Bethesda: National Institutes of Health; 2017. https://clinicaltrials.gov/ct2/show/NCT03136445. Accessed 1 Jan 2019.

  47. ClinicalTrials.gov: American trial using tranexamic acid in thrombocytopenia (A-TREAT). Bethesda: National Institutes of Health; 2016. https://clinicaltrials.gov/ct2/show/NCT02578901. Accessed 1 Jan 2019.

  48. Goksu SS, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, et al. Use of blood transfusion at the end of life: does it have any effects on survival of cancer patients? Asian Pac J Cancer Prev. 2014;15:4251–4.

    Article  Google Scholar 

  49. Gergi M, Soriano-Pisaturo MA. Palliative care issues for transfusion-dependent patients #359. J Palliat Med. 2018;21:1359–60.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, MSC08 4640, University of New Mexico, 1 University of New Mexico, Albuquerque, NM, 87131, USA

    Jay S. Raval

Authors
  1. Jay S. Raval
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jay S. Raval.

Ethics declarations

Conflict of Interest

The author declares that there is no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Palliative Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raval, J.S. Transfusion as a Palliative Strategy. Curr Oncol Rep 21, 92 (2019). https://doi.org/10.1007/s11912-019-0832-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0832-0

Keywords

Search

Navigation